홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /반응

Potassium Carbonate → (R)-1-(4-benzyloxy-3,5-dimethyl-benzyl)-2-(1'-ethoxycarbonylmethyl-4,4'-bipiperidinyl-1-yl)-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

HRID 599760
노트
인쇄 미리보기

반응식

HRID 599760 반응식
[CH2:1]([O:3][C:4](=[O:18])[CH2:5][N:6]1[CH2:11][CH2:10][CH:9]([CH:12]2[CH2:17][CH2:16][NH:15][CH2:14][CH2:13]2)[CH2:8][CH2:7]1)[CH3:2].[O:19]=[C:20]1[N:26]([CH:27]2[CH2:32][CH2:31][N:30]([C:33]([O:35][C@@H:36]([C:54](O)=[O:55])[CH2:37][C:38]3[CH:43]=[C:42]([CH3:44])[C:41]([O:45][CH2:46][C:47]4[CH:52]=[CH:51][CH:50]=[CH:49][CH:48]=4)=[C:40]([CH3:53])[CH:39]=3)=[O:34])[CH2:29][CH2:28]2)[CH2:25][CH2:24][C:23]2[CH:57]=[CH:58][CH:59]=[CH:60][C:22]=2[NH:21]1.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F.C(N(C(C)C)C(C)C)C.C([O-])([O-])=O.[K+].[K+]>C1COCC1.CN(C=O)C>[O:19]=[C:20]1[N:26]([CH:27]2[CH2:32][CH2:31][N:30]([C:33]([O:35][C@H:36]([CH2:37][C:38]3[CH:43]=[C:42]([CH3:44])[C:41]([O:45][CH2:46][C:47]4[CH:52]=[CH:51][CH:50]=[CH:49][CH:48]=4)=[C:40]([CH3:53])[CH:39]=3)[C:54]([N:15]3[CH2:16][CH2:17][CH:12]([CH:9]4[CH2:8][CH2:7][N:6]([CH2:5][C:4]([O:3][CH2:1][CH3:2])=[O:18])[CH2:11][CH2:10]4)[CH2:13][CH2:14]3)=[O:55])=[O:34])[CH2:29][CH2:28]2)[CH2:25][CH2:24][C:23]2[CH:57]=[CH:58][CH:59]=[CH:60][C:22]=2[NH:21]1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

8

반응물 5

HCID 11430Potassium CarbonateHCID 81531DiisopropylethylamineHCID 2733207O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborateHCID 22945803Ethyl[4,4']bipiperidinyl-1-yl-acetateHCID 25208036(R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-carboxy-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

생성물 1

HCID 67273836
(R)-1-(4-benzyloxy-3,5-dimethyl-benzyl)-2-(1'-ethoxycarbonylmethyl-4,4'-bipiperidinyl-1-yl)-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

시약·촉매·용매 2

HCID 6228Dimethylformamide용매HCID 8028Tetrahydrofuran용매

실험 절차

0.99 g (3.90 mmol) ethyl[4,4′]bipiperidinyl-1-yl-acetate were added at RT to a solution of 2.00 g (3.50 mmol) (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-carboxy-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate (Example 1g), 1.25 g (3.90 mmol) TBTU and 0.67 mL (3.90 mmol) ethyldiisopropylamine in 20 mL THF and 5 mL DMF and the reaction mixture was stirred overnight. 15% K2CO3 solution was added, the mixture was extracted exhaustively with EtOAc, the combined organic phases were washed with saturated NaCl solution and dried on Na2SO4. After the elimination of the desiccant and solvent the product was obtained, which was reacted further without purification.

후처리

  1. extractionthe mixture was extracted exhaustively with EtOAc
  2. washthe combined organic phases were washed with saturated NaCl solution
  3. customdried on Na2SO4
  4. customAfter the elimination of the desiccant and solvent the product was obtained
  5. customwhich was reacted further without purification

출처 및 근거

ORD 기록
ord-21606aebcd264c69a086e43637dd8002
출처 데이터셋
uspto-grants-2011_03
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US07897603B2

반응 노트

불러오는 중…

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트